Omalizumab boosts tolerance to multiple food allergies, study finds

A study in The New England Journal of Medicine shows omalizumab increases allergen tolerance in individuals with multiple food allergies, offering a promising standalone treatment option.

FILAMENT HEALTH ENTERS LICENSING AGREEMENT WITH RESET PHARMA – Psychedelic Alpha

Reset Pharma has licensed Filament’s botanical psilocybin drug candidate for a phase 2 clinical trial studying demoralization syndrome VANCOUVER, BC, Aug. 31, 2023 /CNW/ –

August 31, 2023

Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations

Osimertinib (Tagrisso) demonstrated promising clinical activity as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, the nonrandomized UNICORN

November 23, 2023

LJI study details measles virus neutralization

What happens when measles virus meets a human cell? The viral machinery unfolds in just the right way to reveal key pieces that let it

June 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.